BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
24 hedge funds and large institutions have $3.14M invested in BRAINSTORM CELL THERAPUTC in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
9% more funds holding
Funds holding: 22 → 24 (+2)
20% less capital invested
Capital invested by funds: $3.93M → $3.14M (-$789K)
96% less call options, than puts
Call options by funds: $4K | Put options by funds: $98K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$197K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$53.4K |
| 3 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$41.2K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$9.99K |
| 5 |
DOA
D'Orazio & Associates
Falls Church,
Virginia
|
+$2.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$964K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$80.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| 4 |
Bank of New York Mellon
New York
|
-$6.21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| – | -$13K | -359 | Closed |
|
BCLI Hedge Fund Activity: Q3 2016 in Review
24 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2016, worth a combined $3.14M — down 20% from $3.93M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BCLI positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $197K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $964K sold.
- 24 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2016, up from 22 in Q2 2016.
- Funds reported $3.14M of BRAINSTORM CELL THERAPUTC stock for Q3 2016, down 20% quarter-over-quarter.
- 4 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2016 and 2 closed out, a net change of +2 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2016 was Vanguard Group, an estimated $197K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2016 was Perceptive Advisors, an estimated $964K sold.
Based on aggregated 13F filings for Q3 2016.